Genomics|Features|Clopidogrel

Genomics|Features|Clopidogrel

Clopidogrel

Clopidogrel, Pharmacogenomics and Drug Therapy: Where Are We? - February 9, 2015

OPHG classification of CYP2C19 for clopidogrel by level of evidence – Tier 2/Yellow 

A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. 
Ruben L. Osnabrugge et al. Genetics in Medicine, June 19, 2014

Pilot study: incorporation of pharmacogenetic testing in medication therapy management services. 
Haga SB, et al. Pharmacogenomics. 2014 Nov;15(14):1729-1737.

CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. 
Sorich MJ, et al. Circ Cardiovasc Genet. 2014 Dec;7(6):895-902.

Clopidogrel: A multifaceted affair. 
Martínez-Quintana E, J Clin Pharmacol. 2015 Jan;55(1):1-9